Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

288
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
288
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

165
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
165
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

488
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
488
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

238
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
238

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac remodelling and dysfunction in cancer patients receiving cardiotoxic therapies: proteomic and metabolomic profiling.

European heart journal·2026
Same author

Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries.

Journal for immunotherapy of cancer·2026
Same author

Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury.

EBioMedicine·2026
Same author

Correction: Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern.

Journal of neurology·2025
Same author

Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern.

Journal of neurology·2025
Same author

Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Related Experiment Video

Updated: Feb 18, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.3K

Industry Perspective on Biomarker Development and Qualification.

Cory V Gerlach1,2,3, Mazin Derzi4, Shashi K Ramaiah4

  • 1Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts, USA.

Clinical Pharmacology and Therapeutics
|November 17, 2017
PubMed
Summary
This summary is machine-generated.

Biomarker science enables quantitative drug metrics for exposure, efficacy, and safety. This field fosters collaborations to accelerate the delivery of safe medicines, especially for unmet medical needs.

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.5K
Free Radicals in Chemical Biology: from Chemical Behavior to Biomarker Development
14:22

Free Radicals in Chemical Biology: from Chemical Behavior to Biomarker Development

Published on: April 15, 2013

20.8K

Related Experiment Videos

Last Updated: Feb 18, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.3K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.5K
Free Radicals in Chemical Biology: from Chemical Behavior to Biomarker Development
14:22

Free Radicals in Chemical Biology: from Chemical Behavior to Biomarker Development

Published on: April 15, 2013

20.8K

Area of Science:

  • Biomarker science
  • Drug development
  • Translational medicine

Background:

  • Biomarkers are essential tools for pharmaceutical and biotechnology companies.
  • Quantitative metrics for drug exposure, efficacy, and safety are routinely obtained using biomarkers.
  • Biomarkers inform clinical trial design, including patient selection, treatments, and outcomes.

Purpose of the Study:

  • To highlight the role of biomarker science in drug development.
  • To emphasize the potential of biomarker science to foster precompetitive collaborations.
  • To underscore the goal of accelerating the delivery of safe and effective medicines.

Main Methods:

  • Review of biomarker applications in pharmaceutical research.
  • Analysis of the impact of biomarkers on clinical trial design.
  • Exploration of collaborative models in biomarker science.

Main Results:

  • Biomarkers provide critical quantitative data for drug development.
  • Biomarker science facilitates informed decisions in clinical trial design.
  • Precompetitive collaborations in biomarker science can accelerate therapeutic advancements.

Conclusions:

  • Biomarker science is pivotal for advancing pharmaceutical and biotechnology research.
  • Collaboration across academia, industry, and regulatory agencies is key to leveraging biomarker potential.
  • Accelerating the delivery of medicines to patients, particularly in areas of high unmet need, is a primary outcome of effective biomarker utilization.